Cell-based therapies also demonstrated a potential approach to T2DM treatment through generating an infinite supply of insulin-producing cells, mending β cell function, modifying metabolism, and alleviating immunological dysfunction [21, 22]. The gene discussed is INS; the disease is type 2 diabetes mellitus.